文献速递免疫规划卫生政策与健康促进

疫苗初始超说明书使用决策过程的评估:范围综述

Evaluation of the decision-making process underlying the initial off-label use of vaccines: A scoping review.
PubMed 文献 · Vaccine · 2024-08-26

该范围综述评估国家或国际免疫技术咨询组(NITAG)制定新型超说明书推荐时的非标准化决策过程。检索至2022年1月的文献,最终纳入12篇文献及116篇手动检索文献,覆盖1982-2018年。关键结局证据未被系统纳入超说明书推荐,也不一定涉及推荐所关注的确切人群或疫苗;但近年来更多超说明书推荐纳入了关键结局证据,主要为随机对照试验。

要点

  • 关键结局证据未被系统纳入超说明书推荐,也不一定涉及确切人群或疫苗。
  • 近年更多超说明书推荐纳入关键结局证据,主要为随机对照试验。
  • 多数推荐纳入安全性和免疫原性研究及随机对照试验。

核心结论

  • 关键结局证据未被系统纳入超说明书推荐,也不一定涉及推荐所关注的确切人群或疫苗。
  • 近年来更多超说明书推荐纳入关键结局证据,主要为随机对照试验。

研究设计与样本

  • 采用Joanna Briggs Institute框架的范围综述。
  • 检索PubMed、Medline、EMBASE、clinicaltrials.gov、国际临床试验注册库、政府机构与制药网站、全球NITAG网络中心网站及Google Scholar,截至2022年1月。
  • 纳入涉及26种预识别疫苗可预防疾病之一、人类使用、跨时间和国家引入新型变化的推荐,以及关于效力/效果、安全性或免疫原性的证据。
  • 排除快速审批、未标注或个体水平超说明书使用、被动免疫、加强剂量或省级策略的推荐;仅纳入英文和法文文献。
  • 由两名审查者审查标题/摘要和全文,三名进行数据提取。

主要发现

  • 从4023篇文献中纳入12篇,另通过手动检索发现116篇。
  • 在1982-2018年40年跨度内,多数推荐来自最近二十年,且包含证据,除三篇来自1990年代。
  • 多数纳入安全性(69.2%)和免疫原性(65.4%)研究及随机对照试验(57.7%)。
  • 基于适应证的推荐纳入随机对照试验的比例(84.6%)高于基于剂量方案的推荐(30.8%)。
  • 存在涉及与推荐不同人群或疫苗的证据。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This scoping review aimed to assess the non-standardized decision-making process of National or International Immunization Technical Advisory Groups (NITAG) in developing novel off-label recommendations by examining the supportive evidence. METHODS: We used the Joanna Briggs Institute framework. A search strategy was developed with a librarian to identify recommendations and evidence from peer-reviewed and gray literature until January 2022, using PubMed, Medline, EMBASE, clinicaltrials.gov, the International Clinical trials registry, governmental agency and pharmaceutical websites, the Global NITAG Network center website, and Google Scholar. Recommendations involving one of 26 pre-identified vaccine-preventable diseases, human use, and the introduction of a novel change across time and countries, were included. Evidence regarding efficacy/effectiveness, safety, or immunogenicity were included. Recommendations for fast-track approval, unlabeled or individual level off-label use, passive immunization, booster doses or provincial strategies were excluded. Only English and French documents were included. Two reviewers reviewed title/abstracts and full-text documents, and three performed data extraction. The primary outcome was the presence and elements of the evidence. FINDINGS: Out of 4023 documents, 12 were included, and 116 were found through manual search. Over the 40-year span captured (1982-2018), most recommendations were from the last two decades and included evidence, except three from the 1990s. Most included safety (69.2%) and immunogenicity (65.4%) studies and randomized controlled trials (57.7%). Indication-based recommendations included RCTs more often (84.6%) than posology-based recommendations (30.8%). There was evidence involving populations or vaccines different from those in the recommendation. INTERPRETATION: Critical outcomes evidence is not systematically included in off-label recommendations, nor must it involve the exact population or vaccine(s) of concern. However, in recent years, more off-label recommendations include critical outcome evidence, mainly RCTs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Adams K, Diallo D, Tadount F, et al. Evaluation of the decision-making process underlying the initial off-label use of vaccines: A scoping review. Vaccine. 2024. PMID: 39191181. doi:10.1016/j.vaccine.2024.126246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。